Icon

PREVACID IV (nda021566)- (30MG/VIAL)

LANSOPRAZOLE TAKEDA PHARMS NA
30MG/VIAL
No No
2022-Feb-17 Expired
None None
None No
When patients are unable to take the oral formulations, PREVACID I.V. for Injection is indicated as an alternative for the short-term treatment (up to 7 days) of all grades of erosive esophagitis. Once the patient is able to take medications orally, therapy can be switched to an oral formulation of PREVACID for a total of 6 to 8 weeks.
0 0 0
Total Other Developers None
Drugs with Suitability No
30MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.